STOCK TITAN

Talphera to Participate at A.G.P. Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Talphera (Nasdaq: TLPH), a specialty pharmaceutical company, has announced its participation in the A.G.P. Virtual Healthcare Conference on May 21, 2024, at 10:40 a.m. ET. The management will engage in a fireside chat format to discuss the company's innovative therapies developed for medically supervised settings. This session aims to provide insights into Talphera's business strategies and future plans. Attendees can join the webcast through a provided link.

Positive
  • Participation in a major healthcare conference may increase visibility and attract potential investors.
  • Opportunity for management to highlight innovative therapies and business strategies.
  • Scheduled webcast allows for broader audience engagement and potential investor interest.
Negative
  • No new financial data or business developments disclosed in the announcement.
  • The impact on stock price is uncertain as it depends on the content and reception of the fireside chat.
  • No immediate revenue or profit implications from the participation.

SAN MATEO, Calif., May 16, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that management will participate in a fireside chat at the A.G.P. Virtual Healthcare conference May 21, 2024 at 10:40 a.m. ET.

Presentation Information
Presentation Date: Tuesday, May 21, 2024
Presentation Time: 10:40 am ET
Format: Fireside Chat Webcast link: Click here

About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe. This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

Talphera Logo (PRNewsfoto/Talphera, Inc.)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-participate-at-agp-virtual-healthcare-conference-302148401.html

SOURCE Talphera, Inc.

FAQ

When is Talphera participating in the A.G.P. Virtual Healthcare Conference?

Talphera will participate in the A.G.P. Virtual Healthcare Conference on May 21, 2024, at 10:40 a.m. ET.

What is the format of Talphera's participation at the conference?

Talphera's management will participate in a fireside chat format.

What is the significance of Talphera's management participating in the A.G.P. Virtual Healthcare Conference?

The participation allows Talphera to showcase their innovative therapies and discuss business strategies, potentially attracting investors.

How can attendees join Talphera's session at the A.G.P. Virtual Healthcare Conference?

Attendees can join the webcast through a provided link.

What is the stock symbol for Talphera?

The stock symbol for Talphera is TLPH.

Talphera, Inc.

NASDAQ:TLPH

TLPH Rankings

TLPH Latest News

TLPH Stock Data

11.39M
17.03M
1.35%
30.43%
0.2%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
SAN MATEO